Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

India's pharmaceutical exports crossed $31.1 billion in FY2025–26, registering approximately 2% growth over the previous year's record of $30.47 billion — ma...

What Happened

India's pharmaceutical exports crossed $31.1 billion in FY2025–26, registering approximately 2% growth over the previous year's record of $30.47 billion — marking a new all-time high for the sector.
The annual growth rate moderated significantly compared to the 5.6% expansion recorded through April–February FY26, primarily because March 2026 saw a sharp 23% decline in monthly exports — largely due to shipping disruptions caused by West Asian conflict affecting major sea routes.
Formulations, biologicals, vaccines, and AYUSH products led export growth across the year, collectively accounting for roughly 79% of total pharmaceutical export value.
The United States remained India's largest pharmaceutical export destination, absorbing approximately 34% of total exports; the country also benefited from advance US procurement of Indian medicines worth an estimated $1.6 billion above normal levels, driven by tariff-related uncertainty.
India's pharmaceutical industry is now valued at approximately $60 billion, and Pharmexcil (the Pharmaceuticals Export Promotion Council of India) has set a target of $65 billion in exports by 2030.
Despite the record annual figure, headwinds persist: geopolitical disruptions, potential US tariff impositions on pharmaceuticals, and logistics challenges in West Asian shipping lanes cloud the near-term outlook.

Static Topic Bridges

India as the "Pharmacy of the World"

India is the world's largest supplier of generic medicines by volume, accounting for approximately 20% of global generic drug exports. The country ranks third globally in pharmaceutical production by volume and fourteenth by value. Indian generics supply nearly half of all generic prescriptions dispensed in the United States, and serve as the primary source of affordable medicines for many low- and middle-income countries.

India exports pharmaceutical products to over 200 countries and territories.
The sector employs over 3 million people directly and indirectly across manufacturing, research, and distribution.
India has the highest number of US FDA-approved manufacturing plants outside the United States — over 500 facilities as of 2024.
Formulations (finished dosage forms) constitute the bulk of exports; bulk drugs (APIs — Active Pharmaceutical Ingredients) account for the remainder.

Connection to this news: The $31 billion milestone underscores India's structural competitiveness in global pharma, even as geopolitical headwinds test export resilience in FY26.

Pharmexcil and Export Promotion Councils

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) is a statutory body set up under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. Established in 2004, it serves as the nodal agency for promoting pharmaceutical exports and provides market intelligence, regulatory assistance, and trade facilitation to member companies.

Pharmexcil tracks monthly and annual pharmaceutical export data disaggregated by product category and destination market.
The Council administers the Market Access Incentive (MAI) scheme, helping Indian companies penetrate new geographies.
Target: $65 billion in annual pharmaceutical exports by 2030.

Connection to this news: FY26 export data cited in the article is sourced from Pharmexcil's monthly tracking — the organisation's commentary contextualises both the record and the March 2026 dip within longer structural trends.

US Tariff Risks and India's Pharmaceutical Trade

The United States is India's single largest pharmaceutical export market. Any imposition of tariffs on Indian pharmaceutical imports by the US poses a significant risk to Indian pharma revenue, given that 34% of exports flow to the US. Unlike sectors such as steel or electronics, pharmaceuticals have historically been treated with policy caution in tariff negotiations due to their public health implications.

India supplies approximately 47% of US generic drug demand by volume.
A proposed US executive order sought to encourage domestic pharmaceutical manufacturing, raising tariff risks for key exporters including India.
Advance US procurement of approximately $1.6 billion above normal levels in FY26 is interpreted as pre-tariff stockpiling by US buyers.
India's pharma sector is projected to grow to $130 billion by 2030 (domestic + exports combined).

Connection to this news: The moderation in growth rate from an expected 5–6% to approximately 2% for FY26 in dollar terms is partly attributable to the March 2026 slump, itself linked to logistics disruptions and front-loaded US procurement skewing the monthly distribution.

Key Facts & Data

FY26 pharmaceutical exports: $31.1 billion (approximately 2% growth year-on-year)
FY25 pharmaceutical exports: $30.47 billion (previous record)
Growth April–February FY26: 5.6% to $28.29 billion
March 2026 monthly exports: $2.83 billion (down ~23% from $3.68 billion in March 2025)
USA share of Indian pharma exports: ~34% of total
Formulations and biologicals share of exports: ~79%
Pharmexcil export target by 2030: $65 billion
Indian pharmaceutical industry total size: ~$60 billion
Global ranking: 3rd by production volume, largest supplier of generic medicines by volume
US FDA-approved plants in India: 500+
Estimated US pre-tariff stockpiling volume: $1.6 billion above normal procurement